TRPV1在哮喘发病机制中作用的研究进展  

Progress in effect of TRPV1 on pathogenesis of asthma

作　　者：汪枫林 刘德行 WANG Feng-lin;LIU De-xing(Department of Anesthesiology,Affiliated Hospital of Zunyi Medical University,Zunyi 563000,China)

机构地区：[1]遵义医科大学附属医院麻醉科,贵州遵义563000

出　　处：《中国病理生理杂志》2020年第8期1502-1508,共7页Chinese Journal of Pathophysiology

基　　金：国家自然科学基金资助项目(No.81660021)。

摘　　要：哮喘(asthma)是临床常见的呼吸系统疾病之一。目前全世界约有3亿哮喘患者[1],且有证据表明,该病在世界范围内的患病率和死亡率均在逐年上升,预计到2025年,哮喘患者会增加到4亿,同时每年会有约25万人死于哮喘[2]。我国哮喘的患病率约为4.2%,目前全国有超过4570万的哮喘患者,这表明哮喘已成为严重威胁公众健康的疾患[3]。Asthma is a common respiratory disease. In recent years,with the aggravation of environmental pollution,the morbidity and mortality of asthma have shown a significant upward trend. Recent literature provides evidence that transient receptor potential cation channel subfamily V member 1(TRPV1)has both promoting and inhibitory effects on asthma and plays an important role in the development of asthma. Therefore,it is necessary to identify of TRPV1 receptor in asthma,in order to clarify the relationship between TRPV1 receptor and asthma,and to provide theoretical basis for drug research.

关 键 词：瞬时受体电位阳离子通道V亚家族成员1 哮喘 药物治疗 

分 类 号：R562.25[医药卫生—呼吸系统] R363[医药卫生—内科学]